BioCentury
ARTICLE | Clinical News

Dexpramipexole: Additional Phase II data

April 26, 2010 7:00 AM UTC

A post hoc analysis of a double-blind, placebo-controlled, U.S. Phase II trial showed that 50, 150 and 300 mg/day KNS-760704 for 12 weeks displayed a significant dose-dependent trend in reducing treatment failure as measured by both the ALS Functional Rating Scale-Revised (ALSFRS-R) and forced vital capacity. Specifically, treatment failure defined as a >=6 point loss in ALSFRS-R scores from baseline was 35%, 15% and 8% for 50, 150 and 300 mg KNS-760704, respectively, vs. 33% for placebo (p=0.014 for the trend). Treatment failure defined as a reduction in forced vital capacity of >=20% from baseline was 13%, 12% and 4%, respectively, for KNS-760704 vs. 30% for placebo (p=0.028 for the trend). Data were presented at the American Academy of Neurology meeting in Toronto. ...